What's drugs got to do with it? Abbott Q3 fine post-Abbvie
This article was originally published in Clinica
Executive Summary
Abbott’s long-suffering devices business saw growth of 2% during its third fiscal quarter, helping group sales increase by the same amount as it continues to adjust to life without its Abbvie pharma division. The diagnostics division, a long-time stronghold of Abbott, was up 8%. Much of the expansion in Abbott’s devices franchise came from its medical optics unit, which posted 7% revenue growth at $276m. Abbott bolstered its ophthalmology offering earlier this year with the acquisition of OptiMedica (www.clinica.co.uk, 16 July 2013). Vascular and diabetes care sales were both flat at $747m and $319m, respectively. The former has been problematic for some time, with drug-eluting stent sales stalling – but Abbott is pinning its hopes on its bioresorbable vascular scaffold Absorb, as well as the peripheral stent gained with its purchase of IDEV Technologies in July (www.clinica.co.uk, 16 July 2013). Abbott reiterated full-year 2013 EPS guidance of $1.98-2.04 ($1.46-1.52 on a GAAP basis).
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.